Dominion Energy Inc
Change company Symbol lookup
Select an option...
D Dominion Energy Inc
GAIA Gaia Inc
ED Consolidated Edison Inc
RLJ RLJ Lodging Trust
CSCO Cisco Systems Inc
TFSA Terra Income Fund 6 LLC
JPM JPMorgan Chase & Co
NWSA News Corp
DUNE Dune Acquisition Corp
OTRK Ontrak Inc
Go

Utilities : Multi-Utilities | Large Cap Value
Company profile

Dominion Energy, Inc. is a producer and distributor of energy. is focused on providing electricity, natural gas and related services to customers, primarily in the eastern and Rocky Mountain regions of the United States. The Company's segments include Dominion Energy Virginia, Gas Distribution, Dominion Energy South Carolina, and Contracted Assets. Its portfolio of assets includes approximately 30.2 gigawatt (GW) of electric generating capacity, 10,700 miles of electric transmission lines, 78,000 miles of electric distribution lines and 95,700 miles of gas distribution mains and related service facilities, which are supported by 6,000 miles of gas transmission, gathering and storage pipeline. It operates in around 13 states. The Company's operations are conducted through various subsidiaries, including Virginia Electric and Power Company (Virginia Power). Its operations also include Dominion Energy South Carolina, Inc. (DESC).

Postmarket

Last Trade
Delayed
$59.89
0.12 (0.20%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$59.77
Day's Change
-0.85 (-1.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
60.26
Day's Low
59.44
Volume
(Light)
Volume:
3,895,453

10-day average volume:
5,718,103
3,895,453

Kiromic Deadline Alert

6:02 pm ET September 30, 2022 (Newsfile) Print

New York, New York--(Newsfile Corp. - September 30, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and reminds investors of the October 4, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Kiromic: (1) common stock pursuant and/or traceable to the Offering Documents and/or (2) securities between June 25, 2021 and August 13, 2021, both dates inclusive (the "Class Period"). Plaintiff pursues claims against Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934. and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/KRBP.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6455/139056_337e2cb5448dd879_001full.jpg

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

The Complaint alleges that the Offering Documents failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

The Company, however, had received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold. The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021. Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDA's imposition of a clinical hold.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Kiromic's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/139056

comtex tracking

COMTEX_415649587/2523/2022-09-30T18:02:54

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.